Panelists discuss how the final efficacy and safety analysis from the COMMANDS trial (Della Porta et al, Lancet 2024) highlights the role of luspatercept in first-line treatment for lower-risk ...

on the rates of AAFs for Erythropoietin (EPO) Receptor Agonists (ERAs). This study showed that the majority of ERA AAFs occurred on the first sample ever collected for an athlete and that the AAF ...

EPO, erythropoietin; Hb, hemoglobin; s.c., subcutaneous; t.i.w., three times a week. a Hb response is defined as an Hb increase of 2 g/dl from baseline if not stated otherwise. b Hb target level ...

EPO, also referred to as erythropoietin, is a hormone naturally produced by the kidneys that promotes the production of red blood cells. More red blood cells enable your muscles to get more oxygen ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...